drugset / Trial / NCT02613598
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in patients with relapsed or refractory Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL).
Timeline
- Start
- 2016-05-12
- Primary completion
- 2021-06-07
- Completion
- 2021-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 5 mg | — |
| Subject | Ruxolitinib | Small molecule | 10 mg | — |
| Subject | Ruxolitinib | Small molecule | 15 mg | — |
| Subject | Ruxolitinib | Small molecule | 20 mg | — |
| Subject | Ruxolitinib | Small molecule | 25 mg | — |
| Background | Bortezomib | Small molecule | — | — |